<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00930683</url>
  </required_header>
  <id_info>
    <org_study_id>MI-CP180</org_study_id>
    <nct_id>NCT00930683</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Safety and Tolerability of Multiple Doses of MEDI-546 in Adult Subjects With Scleroderma</brief_title>
  <acronym>MEDI-546</acronym>
  <official_title>A Phase 1 Multicenter, Open-label Study to Evaluate the Safety and Tolerability of Single and Multiple Intravenous Doses of MEDI-546, a Fully Human Monoclonal Antibody Directed Against Subunit 1 of the Type I Interferon Receptor, in Adult Subjects With Scleroderma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>MedImmune LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>MedImmune LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and tolerability of a multiple-dosed drug (MEDI-546) in adults with
      scleroderma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of this study is to evaluate the safety and tolerability of single and
      multiple IV doses of MEDI-546 in adult subjects with scleroderma who have skin thickening in
      an area suitable for repeat biopsy.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">May 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The safety and tolerability of MEDI-546 will be assessed primarily by summarizing treatment-emergent AEs and SAEs.</measure>
    <time_frame>Study Day 84 for single-dose; Study Day 105 for multi-dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>The secondary endpoints of the study are to assess the PK, IM, and PD of single and multiple IV doses of MEDI-546 in adult subjects with scleroderma.</measure>
    <time_frame>Study Day 84 for single-dose; Study Day 105 for multi-dose</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">34</enrollment>
  <condition>Scleroderma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>8</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <arm_group>
    <arm_group_label>9</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>MEDI-546</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>0.1 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>0.3 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>1.0 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>3.0 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>10.0 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>0.3 mg/kg MEDI-546 as a weekly IV dose x 4 doses</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>1.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses</description>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>5.0 mg/kg MEDI-546 as a weekly IV dose x 4 doses</description>
    <arm_group_label>8</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEDI-546</intervention_name>
    <description>20.0 mg/kg MEDI-546 as a single IV dose</description>
    <arm_group_label>9</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects ≥ 18 years of age at the time of the first dose of MEDI-546;

          -  Written informed consent and HIPAA authorization (applies to covered entities in the
             US only) obtained from the subject or subject's legal representative;

          -  Must fulfill the American Rheumatism Association (American College of Rheumatology)
             preliminary classification criteria for systemic sclerosis;

          -  Has at least moderate skin thickening (score of at least 2 by modified Rodnan Total
             Skin Score [mRTSS]) in at least one area suitable for repeat biopsy, such as arms,
             legs, or trunk;

          -  Women, unless surgically sterile (including tubal ligation) or at least 2 years
             post-menopausal, must use an effective method of avoiding pregnancy (including oral,
             injectable, transdermal, or implanted contraceptives, intrauterine device, diaphragm
             with spermicide, cervical cap, abstinence, and sterile sexual partner) in addition to
             the use of condoms (male or female condoms with spermicide) from signing of the
             informed consent through the end of the study. Cessation of birth control after this
             point should be discussed with a responsible physician. Men, unless surgically
             sterile, must likewise practice 2 effective methods of birth control (condom with
             spermicide or abstinence) and must use such precautions from Study Day 0 through the
             end of the study;

          -  Ability to complete the study period, including follow-up period through a maximum of
             Study Day 105; and

          -  Willing to forego other forms of experimental treatment during study.

        Exclusion Criteria:

          -  History of allergy or reaction to any component of the MEDI-546 formulation;

          -  Forced vital capacity (FVC) &lt; 60% predicted, diffusing capacity for carbon monoxide
             (DLCO) &lt; 40% predicted, pulmonary hypertension requiring treatment with endothelin
             receptor antagonists or prostacyclin analogues, scleroderma renal crisis within the
             last year, or medically significant malabsorption;

          -  Have received the following medications within 28 days before entry:

               -  Cyclophosphamide at any dose

               -  Systemic cyclosporine at any dose

               -  Thalidomide at any dose

               -  Hydroxychloroquine &gt; 600 mg/day

               -  Mycophenolate mofetil &gt; 3 g/day

               -  Methotrexate &gt; 25 mg/week

               -  Azathioprine &gt; 3 mg/kg/day;

          -  Have received leflunomide &gt; 20 mg/day within 6 months before entry;

          -  Have received fluctuating doses of the following within 28 days before entry:

               -  Antimalarials

               -  Mycophenolate mofetil

               -  Methotrexate

               -  Leflunomide

               -  Azathioprine;

          -  Have received prednisone &gt; 20 mg/day or in fluctuating doses within 14 days before
             entry;

          -  Have received fluctuating doses of nonsteroidal anti-inflammatory drugs (NSAIDs)
             within 14 days before entry;

          -  Treatment with any investigational drug therapy within 28 days before entry into the
             study, B cell-depleting therapies within 12 months before entry, or biologic therapies
             within 30 days or 5 half-lives of the biologic agent, whichever is longer, before
             entry into the study;

          -  In the investigator's opinion, evidence of clinically significant active infection,
             including ongoing, chronic infection, within 28 days before entry;

          -  A history of severe viral infection as judged by the investigators, including severe
             infections of either cytomegalovirus (CMV) or the herpes family such as disseminated
             herpes, herpes encephalitis, ophthalmic herpes;

          -  Herpes zoster infection within 3 months before entry;

          -  Evidence of infection with hepatitis B or C virus, or human immunodeficiency virus
             (HIV)-1 or HIV-2, or active infection with hepatitis A, as determined by results of
             testing at screening;

          -  Vaccination with live attenuated viruses within 28 days before entry;

          -  Pregnancy (women, unless surgically sterile or at least 2 years post-menopausal, must
             have a negative serum pregnancy test within 28 days before receiving MEDI-546 and a
             negative urine pregnancy test on days of MEDI-546 administration before receiving
             MEDI-546);

          -  Breastfeeding or lactating women;

          -  History of primary immunodeficiency;

          -  History of alcohol or drug abuse &lt; 1 year prior to entry;

          -  History of cancer except basal cell carcinoma or in situ carcinoma of the cervix
             treated with apparent success with curative therapy &gt; 1 year prior to entry;

          -  History of active tuberculosis (TB) infection or latent TB infection without
             completion of an appropriate course of treatment;

          -  Newly positive TB skin test (defined as a reaction ≥ 10 mm in diameter if not on
             systemic immunosuppressive medication or ≥ 5 mm if on systemic immunosuppressive
             medication) without concomitant prophylactic therapy;

          -  Elective surgery planned from the time of signing of the informed consent through end
             of study;

          -  At screening blood tests (within 28 days before entry), any of the following:

               -  Aspartate aminotransferase (AST) &gt; 2.5 x upper limit of the normal range (ULN),
                  unless due to Myositis

               -  Alanine aminotransferase (ALT) &gt; 2.5 x ULN

               -  Creatinine &gt; 4.0 mg/dL

               -  Creatinine &gt; 4.0 mg/dL

               -  Neutrophils &lt; 1,500/mm3

               -  Platelet count &lt; 50,000/mm3;

          -  History of any disease, evidence of any current disease (other than scleroderma), any
             finding upon physical examination, chest x-ray, or any laboratory abnormality that, in
             the opinion of the investigator or medical monitor, may compromise the safety of the
             subject in the study or confound the analysis of the study; or

          -  Any employee of the research site who is involved with the conduct of the study.

          -  History of vasculitis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Yoo, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>MedImmune LLC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metroplex Clinical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Utah Medical Center</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>June 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2009</study_first_posted>
  <last_update_submitted>May 7, 2012</last_update_submitted>
  <last_update_submitted_qc>May 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scleroderma, Systemic</mesh_term>
    <mesh_term>Scleroderma, Diffuse</mesh_term>
    <mesh_term>Scleroderma, Localized</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

